Showing papers in "Journal of Clinical Lipidology in 2013"

TL;DR: On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dys Lipidemia.

TL;DR: In this article, an expert panel was formed to evaluate the current status of HDL-C as a therapeutic target; to review the current state of knowledge of HDL particle structure, composition, and function; and to identify the salient questions yet to be answered about the role of HDL in either preventing or contributing to atherosclerotic disease.

TL;DR: Statin-related muscle side effects are common and contribute significantly to rates of discontinuation, switching, and non-adherence, and improved physician patient communication about side effects and benefits of statins are necessary to improve both adherence and outcomes.

TL;DR: RBCs provide a more reliable estimate of a patient's chronic EPA + DHA status than does plasma, similar to hemoglobin A1c, which is not affected by an acute glycemic deviation.

TL;DR: Hazelnut-enriched diets may exert antiatherogenic effect by improving endothelial function, preventing LDL oxidation, and inflammatory markers, in addition to their lipid and lipoprotein-lowering effects.

TL;DR: Currently, the FDA is not regulating manufacturers of RYR products and as a result, many of these products may contain monacolin K and toxins such as citrinin.

TL;DR: These results demonstrate that on a moderate carbohydrate background diet, accompanied by weight loss, the inclusion of whole eggs improves inflammation to a greater extent than yolk-free egg substitute in those with metabolic syndrome.

TL;DR: In Japanese patients with modest hypertriglyceridemia who also underwent lifestyle intervention, TAK-085 4 g/day reduced TG more than EPA-E 1.8 g/ day and was well-tolerated.

TL;DR: TAK-085 was safe and well tolerated for up to 52 weeks of treatment in Japanese patients with hypertriglyceridemia undergoing lifestyle modification and reductions in triglyceride levels achieved after 4 weeks were maintained at 52 weeks.

TL;DR: The genetics of dyslipidemia, obesity, and nonalcoholic fatty liver disease are central in triggering progression of the syndrome to overt expression of disease traits and have become a key focus of interest for early detection and for designing prevention and treatments.

TL;DR: The risk of habdomyolysis among hospitalized patients receiving statins was low; no difference among the available statinswas evident and current findings already offer guidance to physicians.

TL;DR: Fenofibrate and ER niacin increased plasma HDL-C level similarly, but modulated HDL particle size distribution differently; however, these changes did not result in differential effects on serum CECs.

TL;DR: Available data regarding the efficacy, safety and tolerability of mipomersen, including results at up to 104 weeks of therapy, support the use of mIPomersen for the treatment of FH.

TL;DR: A high proportion of individuals in the community have dyslipidemia, often associated with modifiable risk factors, and the situation demands programs aimed at risk factor reduction.

TL;DR: Randomized controlled trials show wide variability in the effects of HIT on lipid management outcomes, and evidence suggests that multilevel HIT approaches that target not only providers but include patients and systems approaches will be needed to improve lipid treatment, adherence and quality.

TL;DR: This study will determine the utility of CoQ10 for reducing pain intensity in myalgic patients and will provide guidance for clinicians treating patients with hypercholesterolemia who are intolerant to statins.

TL;DR: Mixed evidence is found for independent relationships between low total and LDL cholesterol levels and impaired psychological health among middle-aged adults.

TL;DR: Astute clinical observation of individual patients and their families with atypical lipid profiles, followed by sequencing of the affected individual, has the potential to lead to important findings regarding the genetic mutations that cause lipid abnormalities.

TL;DR: The low variance in carotid IMT explained by traditional risk factors suggests nontraditional risk factors may be important to assess to better understand the contributors to early-stage atherosclerosis in adolescents and young adults with T2D.

TL;DR: Recent data support the LDL-C-lowering efficacy of low-dose titrated lomitapide in patients with homozygous FH; however, concerns regarding increased hepatic fat will need to be addressed in long-term safety studies.

TL;DR: The workshop discussions focused on how low-density lipoprotein cholesterol (LDL-C) goal attainment can be enhanced with the use of health information technology (HIT) in different clinical settings.

TL;DR: In this managed-care setting, among patients with high risk of cardiovascular disease who were not at low-density lipoprotein cholesterol (LDL-C) goal, statins were usually started at medium-potency doses without being titrated up, whereas nearly one-half had a discontinuation of LLT within 12 months.

TL;DR: Hypothyroidism is more prevalent in those with statin intolerance, both in males and, especially, in females, and people with hypothyroidistan are less likely to have a prescription for a statin at follow-up than those without hypothyroism.

TL;DR: Orlistat can be considered effective in augmenting the effect of a low-fat diet and reducing risk for pancreatitis, and the data support the need for more effective long-term treatments that not only prevent pancreatitis but also offset cardiovascular risk.

TL;DR: The hypothesis that reducing dyslipidemia with weight loss reduces the MCE capacity of MetS plasma to that of NL plasma is tested and it is found that the elevated apolipoprotein B lipoproteins are a cholesterol sink that increases MCE in patients with MetS.

TL;DR: The data showing decreased levels of cholesterol efflux mediators in plasma and cells may suggest that the overallolesterol efflux capacity is impaired in homozygous FH patients, however, LDL apheresis may maintain cholesterol Efflux capacity, despite a lowering levels of high-density lipoprotein cholesterol and apoA-I.

TL;DR: A patient with a unique phenotype of Tangier disease from a novel splice site mutation in the ABCA1 gene is described that is associated with a central nervous system presentation resembling multiple sclerosis, and the presence of premature atherosclerosis.